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Abstract
Rheumatoid arthritis (RA) is associated with neuroendocrine
and immunologic dysfunction leading to rheumatoid cachexia.
Although excess proinflammatory cytokines can decrease
somatotropic axis activity, little is known about the effects of RA
on growth hormone/insulin-like growth factor-1 (GH/IGF-I) axis
function. We tested the hypothesis that patients with active RA
exhibit decreased GH/IGF-I axis activity. To do so, we
conducted a pilot case-control study at a clinical research
center in 7 pre- and perimenopausal women with active RA and
10 age- and body mass index-matched healthy women.
Participants underwent blood sampling every 20 minutes for 24
hours (8 a.m. to 8 a.m.), and sera were assayed for GH, cortisol,
and dehydroepiandrosterone (DHEA). Sera obtained after
overnight fasting were assayed for IGF-I, IGF-binding protein
(IGFBP)-1, IGFBP-3, C-reactive protein (CRP), interleukin-6 (IL-
6), glucose, insulin, and lipids. Body composition and bone
mineral density were evaluated by DEXA (dual emission x-ray
absorptiometry) scans. In patients with RA, mean disease
duration was 7.6 ± 6.8 years, and erythrocyte sedimentation
rate, CRP, and IL-6 were elevated. GH half-life was shorter than
in control subjects (p = 0.0037), with no other significant group
differences in GH deconvolution parameters or approximate
entropy scores. IGF-I (p = 0.05) and IGFBP-3 (p = 0.058) were
lower, whereas IGFBP-1 tended to be higher (p = 0.066), in
patients with RA, with nonsignificantly increased 24-hour total
GH production rates. There were no significant group
differences in cortisol or DHEA secretion. Lean body mass was
lower in patients with RA (p = 0.019), particularly in the legs (p
= 0.01). Women with active RA exhibit a trend toward GH
insensitivity and relatively diminished diurnal cortisol and DHEA
secretion for their state of inflammation. Whether these changes
contribute to rheumatoid cachexia remains to be determined.
Trial registration number NCT00034060.
Introduction
Rheumatoid arthritis (RA) is a chronic, autoimmune-mediated,
inflammatory arthritis that occurs in approximately 0.5% to 1%
of the general population and affects women 2.5 times more
often than it does men. Chronic imbalance among neuroendo-
crine, immunologic, and microvascular systems leads to 'rheu-
ACTH = adrenocorticotropic hormone; ApEn = approximate entropy; BMD = bone mineral density; BMI = body mass index; CRH = corticotropin-
releasing hormone; CRP = C-reactive protein; CV = coefficient of variation; DEXA = dual energy x-ray absorptiometry; DHEA = dehydroepiandros-
terone; ESR = erythrocyte sedimentation rate; FSH = follicle-stimulating hormone; GFR = glomerular filtration rate; GH = growth hormone; HDL = 
high-density lipoprotein; HPA = hypothalamic-pituitary-adrenal; IGF-I = insulin-like growth factor-1; IGFBP = insulin-like growth factor-binding protein; 
IL-6 = interleukin-6; IV = intravenous; LBM = lean body mass; MDRD = Modification of Diet in Renal Disease; NIH = National Institutes of Health; RA 
= rheumatoid arthritis; RIA = radioimmunoassay; TNF = tumor necrosis factor.Arthritis Research & Therapy    Vol 9 No 4    Blackman et al.
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matoid cachexia,' accelerated cardiovascular disease, and
enhanced mortality in patients with RA [1-3]. RA cachexia is
manifested by losses of muscle and bone mass, resulting in
part from augmented cytokine activity [4].
Progressive decline in the secretion of growth hormone (GH)
and its principal circulating and tissue mediator, insulin-like
growth factor-1 (IGF-I), is one of the key pathophysiological
mechanisms contributing to the cachexia of normal aging [5].
In a mouse model, overexpression of the inflammatory
cytokine, interleukin-6 (IL-6), has been associated with sup-
pression of the GH/IGF-I axis [6]. However, few studies have
investigated the GH/IGF-I axis in patients with active RA [7].
The hypothalamic-pituitary-adrenal (HPA) axis is also affected
to varying degrees in patients with RA, independent of the use
of exogenous glucocorticoids. Most reports indicate that cir-
culating levels of cortisol and dehydroepiandrosterone
(DHEA) are normal, and not elevated, in the setting of
increased proinflammatory activity, suggesting a relative
hypoadrenalism in patients with RA, possibly due to reduced
corticotropin-releasing hormone (CRH) activity [8,9].
We hypothesized that the excess of systemically released
inflammatory cytokines characteristic of patients with active
RA suppresses GH/IGF-I axis activity and that the combined
effects of disordered endocrine (anabolic balance) and
immune function contribute to changes in body composition
predisposing patients with RA to sarcopenia, increased body
fat, and osteopenia. The primary goal of this study was to
determine whether spontaneous, diurnal GH secretion and
a.m serum IGF-I concentrations are decreased in pre- and per-
imenopausal women with active RA. In addition, we evaluated
ultradian and pulsatile cortisol and DHEA secretory dynamics,
body composition, and metabolic outcomes in these same
patients and compared them with values in healthy control
subjects.
Materials and methods
Study subjects
We recruited seven premenopausal and perimenopausal
women who fulfilled the American College of Rheumatology
criteria for active RA as defined by at least nine tender and six
swollen joints, erythrocyte sedimentation rate (ESR) of greater
than 28 mm/hour or C-reactive protein (CRP) of greater than
2.0 mg/dl, and morning stiffness of greater than 45 minutes.
Use of nonsteroidal anti-inflammatory drugs and/or hydroxy-
chloroquine was permitted. However, drug doses had to have
been stable for at least 1 month prior to enrollment and they
were held constant during the study unless toxicity required
dose reduction. Patients were allowed to be on stable doses
of methotrexate, but past use of all other disease-modifying
agents (for example, sulfasalazine or cyclosporin) or anti-tumor
necrosis factor (TNF) agents (for example, etanercept or inflix-
imab) or glucocorticoid was allowed only if (a) the total expo-
sure had not been more than 3 months and (b) there had been
no exposure in the 3 months prior to enrollment. No patients
were using alternative treatments such as nutritional supple-
ments, acupuncture, or chiropractic therapy, and all were
physically active. At the time of study screening, all patients
with RA were either premenopausal, as defined by a history of
normal menses and normal estradiol (>30 pg/ml) plus follicle-
stimulating hormone (FSH) levels, or perimenopausal, with a
history of irregular menses during the 12 months prior to study
and normal estradiol (>30 pg/ml) plus elevated FSH (>30 IU/
ml) levels. Ten healthy women matched for age (± 3 years),
body mass index (BMI) (± 1.0), and menstrual and reproduc-
tive hormone status were also included. Research subjects
were excluded if they were obese (BMI > 30), had used pre-
scription or over-the-counter estrogen/progesterone prepara-
tions during the 2 weeks prior to screening, were pregnant, or
had a history of cancer, renal disease, liver disease, anemia,
endocrine or metabolic disorders, active infections or live vac-
cinations (in the 3 months prior to enrollment), depression, or
any other comorbid medical or psychiatric condition known to
influence the GH-IGF-I or HPA axis. The study was approved
by the Institutional Review Board of the National Institute of
Diabetes and Digestive and Kidney Diseases and the National
Institute of Arthritis and Musculoskeletal and Skin Diseases,
National Institutes of Health (NIH), and all participants pro-
vided written informed consent.
Study design
Study participants were admitted to the Clinical Research
Center on the evening of day 1 to allow overnight adaptation
and provision of their usual ad libitum diet in the form of a light
dinner. Participants then remained fasting overnight. At 7 a.m.
on day 2, an intravenous (IV) catheter was inserted into a fore-
arm vein and was kept open with 0.9% sodium chloride. At 8
a.m., after the overnight fast, 30 ml of blood was collected for
measurements of serum IGF-I, IGF-binding protein (IGFBP)-1
and IGFBP-3, glucose, insulin, lipid profile, CRP, and IL-6.
From 8 a.m. on day 2 to 8 a.m. on day 3, blood samples (2.5
ml) were collected at 20-minute intervals, and sera were
stored at -80°C for subsequent measurements of GH, cortisol,
and DHEA. On the morning of day 3, at the completion of the
24-hour frequent blood sampling, the IV catheter was
removed, and study participants were asked to complete a vis-
ual analog scale for pain and global health. Anthropometric
measurements, including body weight, height, and BMI, were
obtained, and a dual energy x-ray absorptiometry (DEXA) scan
(Hologic QDR 4500; Hologic Inc., Bedford, MA, USA) was
performed to assess total and regional lean body mass (LBM),
total fat mass, and bone mineral density (BMD) at six sites
(postero-anterior spine, total femur, femoral neck, trochanter,
Ward's area, and distal radius). Participants were discharged
early in the afternoon of day 3.
Biochemical assays
Serum obtained at 8 a.m. after an overnight fast was used for
measurements of IGF-I, IGFBP-1 and IGFBP-3, CRP, and IL-Available online http://arthritis-research.com/content/9/4/R73
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6. GH and cortisol concentrations were measured in sera
obtained from the 24-hour (every 20 minutes) sampling tech-
nique by means of a chemiluminescence assay (Nichols Insti-
tute Diagnostics Inc., San Clemente, CA, USA). Sensitivity
and intra- and interassay coefficients of variation (CVs) of the
GH assay were 0.1 ng/ml and 2.8% and 7.5%, respectively.
Corresponding values for the cortisol assay were 0.9 µg/dl
and 4.4% and 11%, respectively. IGF-I, IGFBP-1, and IGFBP-
3 were measured at Endocrine Sciences (Tarzana, CA, USA).
IGF-I was measured by a blocking radioimmunoassay (RIA)
after acid alcohol extraction. IGFBP-1 and IGFBP-3 were
measured by RIA in dilute serum. The sensitivity of the IGF-I
assay was 63.4 ng/ml, and intra- and inter-assay CVs were
6.5% and 9.4%, respectively. Corresponding values for the
IGFBP-1 assay were 5 ng/ml, with intra- and inter-assay CVs
of 6% and 12%, and those for the IGFBP-3 assay were 0.8
mg/l, with intra- and inter-assay CVs of 13% and 17%, respec-
tively. Serum levels of DHEA were measured in the every-20-
minute sampling specimens by enzyme-linked immunosorbent
assay at Diagnostic Systems Laboratories (Webster, TX,
USA). The sensitivity of the assay was 0.1 ng/ml, with intra-
and interassay CVs of 10.7% and 17.0%, respectively. DHEA
measurements correlated strongly (r2 = 0.87) with values
quantified by tandem gas chromatography-mass spectrome-
try. IL-6 was measured using commercially available kits
(Quantikine HS Human IL-6 Immunoassay; R&D Systems, Inc.,
Minneapolis, MN, USA). The sensitivity of the IL-6 assay was
0.039 pg/ml with intra- and inter-assay CVs of 7.8% and
7.2%, respectively. Serum concentrations of CRP were meas-
ured in the NIH Clinical Center's Department of Laboratory
Medicine by high-sensitivity nephelometric assay on an
IMMAGE Immunochemistry System (Beckman Coulter, Fuller-
ton, CA, USA). The sensitivity was 0.1 mg/dl and the intra- and
interassay CVs were 2.6% and 3.0%, respectively. Serum
concentrations of glucose, insulin, total and high-density lipo-
protein (HDL) cholesterol, and triglycerides were measured by
routine chemical techniques in the NIH Clinical Center's
Department of Laboratory Medicine.
Analysis of hormone secretion
Multi-parameter deconvolution analysis (Deconv) was applied
to determine quantitative properties of underlying secretory
bursts and endogenous hormone half-life of GH, cortisol, and
DHEA [10]. Regularity in GH, cortisol, or DHEA concentra-
tion-time series was quantified using approximate entropy
(ApEn) as previously described [11].
Twenty-four-hour rhythmicity of serum GH, cortisol, or DHEA
concentrations was quantified by cosinor analysis [12]. This
procedure entails unweighted regression of a cosine function
of 1,440-minute periodicity on the observed hormone concen-
tration-time series. Ninety-five percent statistical confidence
intervals are determined for the fitted amplitude (50% of the
nadir-zenith difference), mesor (cosine mean), and acrophase
(clock time of calculated maximum value).
Statistical analysis
After verification of lack of difference between women with RA
and their healthy controls with respect to age and BMI, an
exact Wilcoxon rank sum test was used to compare results
between groups. P values for the primary outcome measures
(total GH level and IGF-I) were adjusted for multiple compari-
sons by the Hochberg method and considered significant if
the  p  value was less than 0.05 [13]. Planned secondary
parameters (IGFBPs, IL-6, DHEA, cortisol, and metabolic and
lipid parameters) were considered significant if the p value
was less than 0.01. When unplanned exploratory parameters
(DEXA measurements of body fat and BMD) were compared
between groups, a p value of less than 0.005 was considered
significant.
Results
Patient characteristics
There were no significant differences in age or BMI between
patients with RA and control subjects. Patients with RA were
predominantly Hispanic-American and African-American,
whereas control subjects were primarily Caucasian and Afri-
can-American. Patients with RA had experienced their disease
for a mean ± standard error of the mean of 7.6 ± 2.6 years, had
23.2 ± 3.7 swollen joints and 23.3 ± 2.8 tender joints, had
increased pain and physical component summary scores, and
exhibited elevated values for ESR, CRP, and IL-6 (Table 1).
Hormone measures
Except for a shorter GH half-life in patients with RA, there were
no significant differences in circadian GH deconvolution
parameters or ApEn scores in patients with RA versus control
subjects (Table 2). However, in RA patients as compared with
their healthy counterparts, the mean serum concentration of
IGF-I in the morning was lower (p = 0.05), IGFBP-3 exhibited
a trend toward being lower, and IGFBP-1 concentrations
tended to be higher. The changes in IGF-I and IGFBPs in
patients with RA were associated with nonsignificantly higher
24-hour total GH production rates.
We also examined the circadian characteristics of cortisol and
DHEA secretion. There were no significant differences in the
total production rate, mean or integrated concentrations, or
regularity (ApEn) of circadian cortisol or DHEA secretion in RA
patients compared with healthy control subjects (Table 3). The
amplitudes and acrophases of 24-hour cortisol or DHEA
rhythms were also similar in the two groups (data not shown).
Body composition and metabolic profile
Total LBM, determined by DEXA, was lower in patients with
RA versus control subjects, with disproportionately greater
reductions in the legs versus the arms (Table 4). In contrast,
there were no significant group differences in absolute or per-
centage total fat mass or in BMD values of the spine, hip, or
radius (Table 4). After an overnight fast, serum creatinine and
(to a lesser extent) total cholesterol concentrations wereArthritis Research & Therapy    Vol 9 No 4    Blackman et al.
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Table 1
Characteristics of patients with rheumatoid arthritis
Variables Rheumatoid arthritis (n = 7) Controls (n = 10)
Age (years) 36.3 ± 3.7 41.8 ± 2.1
Race (n)
Caucasian 06
Hispanic 50
African-American 2 4
Duration of rheumatoid arthritis (years) 7.6 ± 2.6 NA
Swollen joint counta 23.2 ± 3.7 NA
Tender joint counta 23.3 ± 2.8 NA
Swollen joint scorea 31.7 ± 6.1 NA
Tender joint scorea 34.0 ± 5.5 NA
Pain (visual analog) scoresb 7.1 ± 0.6 NA
Physical component summary scorec 28.0 ± 2.1 55.3 ± 1.3
Erythrocyte sedimentation rate (mm/hour) 69.1 ± 11.3 15.9 ± 1.6
C-reactive protein (mg/dl) 3.7 ± 1.3 0.4 ± 0.02
Interleukin-6 (pg/ml) 25.6 ± 9.8 5.3 ± 2.4
Values are presented as mean ± standard error of the mean. NA, not applicable. aSixty-eight joints were examined for tenderness, and 66 joints 
were examined for swelling; bvisual analog scale (cm) ranged from 0 (best) to 10 (worst); cvalues represent percentile scores.
Table 2
GH secretory parameters and morning serum concentrations of IGF-I and IGFBPs in rheumatoid arthritis patients and control 
subjects
Variables Rheumatoid arthritis (n = 7) Controls (n = 10) P value
GH basal secretion (µg/liter per minute) 0.02 ± 0.00 0.01 ± 0.00 NS
GH mass/burst (µg/liter) 6.12 ± 1.03 6.71 ± 1.20 NS
GH burst frequency (number/24 hours) 13.7 ± 1.9 9.8 ± 1.2 NS
GH amplitude (µg/liter per minute) 0.430 ± 0.10 0.29 ± 0.06 NS
GH total production rate (µg/liter per 24 hours) 114 ± 26 73 ± 74 0.28
Mean GH (µg/liter) 0.91 ± 0.14 1.20 ± 0.17 NS
Integrated GH (µg/liter per minute) 1,316 ± 201 1,717 ± 245 NS
GH half-life (minutes) 9.2 ± 1.2 14.6 ± 0.9 0.0037
GH approximate entropy 0.75 ± 0.07 0.70 ± 0.09 NS
IGF-I (ng/ml) 129 ± 27 205 ± 25 0.05
IGFBP-1 (ng/ml) 42.1 ± 16 8.3 ± 2 0.066
IGFBP-3 (ng/ml) 2.2 ± 0.2 2.6 ± 0.1 0.058
Values are presented as mean ± standard error. P value indicates the significance of the difference in each parameter value between patients and 
control subjects. See 'Statistical analysis' section for details. GH, growth hormone; IGF-I, insulin-like growth factor-1; IGFBP, insulin-like growth 
factor-binding protein; NS, not significant (p > 0.10 when not explicitly reported).Available online http://arthritis-research.com/content/9/4/R73
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Table 3
Diurnal cortisol and dehydroepiandrosterone secretory parameters in rheumatoid arthritis patients and control subjects
Cortisol (µg/dl) Dehydroepiandrosterone (ng/ml)
Variables Rheumatoid arthritis
(n = 7)
Controls
(n = 10)
Rheumatoid arthritis
(n = 7)
Controls 
n = 10)
Total production rate (per 24 hours) 71 ± 8 75 ± 7 280 ± 108 203 ± 50
Mean concentration 7.12 ± 0.62 6.48 ± 0.33 7.02 ± 2.28 6.76 ± 0.89
Integrated concentration (per minute) 10,094 ± 841 9,218 ± 598 9,950 ± 3,252 9,401 ± 1,275
Approximate entropy 0.93 ± 0.08 0.91 ± 0.08 1.22 ± 0.08 1.18 ± 0.06
Values are presented as mean ± standard error. All of the differences had p values greater than 0.10.
Table 4
Body composition and metabolic outcomes in rheumatoid arthritis patients and control subjects
Variables Rheumatoid arthritis (n = 7) Controls (n = 10) P value
Body mass index (kg/m2) 26.9 ± 0.9 27.8 ± 0.9 NS
Total lean body mass (kg) 40.3 ± 1.1 46.1 ± 1.6 0.019
Lean body mass, both arms (kg) 3.9 ± 0.3 4.6 ± 0.2 0.03
Lean body mass, both legs (kg) 12.5 ± 0.4 15.4 ± 0.7 0.01
Total body fat mass (kg) 23.7 ± 0.8 25.8 ± 1.5 NS
Body fat (percentage) 35.9 ± 1.1 34.6 ± 1.0 NS
Bone mineral density (g/cm2)a
Femoral neck 0.85 ± 0.03 0.82 ± 0.05 NS
Trochanter 0.69 ± 0.03 0.75 ± 0.05 NS
Ward's area 0.74 ± 0.03 0.74 ± 0.06 NS
Lumbar spine (L2-L4) 0.790 ± 0.03 0.81 ± 0.04 NS
Distal radius 0.68 ± 0.01 0.72 ± 0.02 NS
Serum creatinine (mg/dl) 0.57 ± 0.05 0.79 ± 0.02 <0.001
Fasting blood glucose (mg/dl) 90.6 ± 1.9 91.7 ± 2.2 NS
Fasting insulin (µU/liter) 11.20 ± 3.60 7.40 ± 0.70 NS
Quantitative Insulin Sensitivity 
Check Index
0.35 ± 0.01 0.36 ± 0.01 NS
Total cholesterol (mg/dl) 156 ± 13 198 ± 13 0.046
Low-density lipoprotein 
cholesterol (mg/dl)
96.6 ± 11.2 124.4 ± 13.3 NS
High-density lipoprotein 
cholesterol (mg/dl)
47.90 ± 5.30 57.7 ± 4.2 NS
Triglycerides (mg/dl) 97.6 ± 9.2 109.3 ± 11.5 NS
Values are presented as mean ± standard error. P value indicates the significance of the difference in each parameter value between patients and 
control subjects. aOne patient with rheumatoid arthritis was removed from the bone mineral density analysis because of her diagnosis of 
osteosclerosis. NS, not significant (p > 0.10).Arthritis Research & Therapy    Vol 9 No 4    Blackman et al.
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lower, whereas serum insulin concentrations were slightly but
nonsignificantly higher in patients with RA; there were no
group differences in glucose, QUICKI (Quantitative Insulin
Sensitivity Check Index), low-density lipoprotein or HDL cho-
lesterol, or triglyceride values.
Discussion
In this study, a well-characterized group of pre- and perimeno-
pausal women with clinically and biochemically active RA,
compared with age- and BMI-matched healthy women, exhib-
ited reduced morning serum concentrations of IGF-I, a trend
toward lower IGFBP-3, accelerated GH circulatory half-life,
trends toward increases in IGFBP-1 and IL-6 levels (and total
GH production), unaltered pulsatile, nycthemeral, or feedback-
sensitive (entropic) features of cortisol or DHEA secretion,
and substantially decreased LBM, especially in the legs.
Studies evaluating the GH-IGF-I-IGFBP-3 system in patients
with RA have yielded contradictory and inconsistent results
[7,9,13-18], in part because of differences in the ages, gen-
ders, and numbers of patients studied, disease activity, and
use of glucocorticoids and other disease-modifying agents. In
the current investigation, the mean serum concentration of
IGF-I in the morning was lower in patients with RA versus con-
trol subjects and IGFBP-3 also exhibited a similar trend, find-
ings consistent with some studies [15,16] but not with others
[18,19]. In the latter four studies, there were no apparent rela-
tionships between disease activity and IGF-I and IGFBP-3 lev-
els. Most circulating IGF-I is produced by the liver in response
to GH and mediates many of the anabolic actions of GH. In
comparison, local IGF-I production within target tissues is reg-
ulated by both GH-dependent and -independent mechanisms.
IGF-I circulates as a ternary complex with IGFBP-3 and the
acid-labile subunit, and both liver-derived proteins are under
the control of GH [20]. Reduced serum concentrations of
IGFBP-3 can result from a primary decrease in IGFBP-3 pro-
duction, or secondarily, due to a reduction in IGF-I. IGFBP-3
stabilizes circulating IGF-I, and reductions in IGFBP-3 can
contribute to a decrease in IGF-I levels (due to decreased sta-
bility of the complex). IGFBP-1, which is also derived from the
liver, binds to free IGF-I and is negatively regulated by nutrition
and insulin [20]. Elevated IGFBP-1 levels as observed in
patients with RA could further reduce free IGF-I availability and
action [21].
In this study, mean GH concentrations in patients with RA
were not significantly different from those in age- and BMI-
matched healthy volunteers. However, the nonsignificant
increase in GH total production rate which we observed was
accompanied by a significant reduction in the calculated GH
half-life in patients with RA, and that may explain the
unchanged mean and integrated circulating GH concentra-
tions. Circulating GH is cleared primarily by the liver and kid-
ney. The rate of GH elimination is directly related to the plasma
total free GH concentration, relative obesity, and renal function
[22]. The exact mechanism (or mechanisms) of the reduced
GH half-life in our patients with RA is unclear, and the appar-
ent change in calculated GH elimination kinetics in patients
with RA requires further confirmation by more robust, isotopic
infusion techniques. However, some potential factors may
explain the reduced GH half-life in our patients with RA. GH is
catabolised in the kidney after filtration and absorption by the
proximal tubules. Consequently, GH clearance rate is deter-
mined by the glomerular filtration rate (GFR). In this study, esti-
mated GFR (using the LBM-adjusted Cockcroft and Gault
formula or the formula derived from the Modification of Diet in
Renal Disease [MDRD] study [23,24]) was higher in RA
patients as compared with healthy volunteers (MDRD-derived
GFR: 123.9 ± 14.2 versus 77.2 ± 8.1 ml/minute per 1.73 m2;
p = 0.0015). This may have contributed to the shortened GH
half-life. In addition, GH half-life is determined by the volume of
distribution. In this study, LBM is significantly reduced in RA
patients as compared with healthy controls. Consequently, it
is possible that the volume of distribution for GH is also
reduced. Thus, increased renal clearance and reduced volume
of distribution may enhance GH elimination. Of note, renal
impairment in RA occurs late in the course of disease and is
increased in patients who develop vasculitis or amyloidosis or
as a complication from drug therapy. The most potentially
nephrotoxic agents – gold salts, penicillamine, and
cyclosporine – are no longer commonly used. Thus, the finding
of reduced GH half-life observed in this study may be more
prominent in earlier disease and in patients who have not
received long-term disease-modifying anti-rheumatic drug
therapy.
The pattern of reduced circulating IGF-I and IGFBP-3 with an
unchanged GH total production rate in patients with RA, as
observed in our study, appears to be consistent with GH
resistance or insensitivity [20,25]. Although the exact mecha-
nisms for GH insensitivity in patients with RA are unclear, GH
resistance has been observed in inflammatory and heightened
catabolic states [26]. Cytokine exposure (IL-1, TNF-α, and
endotoxin) in animals decreases IGF-I synthesis [27,28], and
reduced IGF-I levels occur in patients with chronic liver dis-
ease [29] and in critically ill patients [26]. Similarly, cytokines
upregulate IGFBP-1 synthesis [30]. Of note is the recent
report by Nemet and colleagues [31] demonstrating that
short-term infusion of recombinant human IL-6 in healthy
young men to levels typically occurring during exercise
decreases serum concentrations of IGF-I and increases those
of GH and IGFBP-1. Our findings of increased inflammatory
markers (ESR, CRP, and IL-6), along with reduced IGF-I and
IGFBP-3, are consistent with data from some but not all prior
studies. Rall and colleagues [19] found no alterations in GH
kinetics (frequent sampling followed by deconvolution) in RA
patients compared with age- and BMI-matched control sub-
jects. However, the authors did observe a trend toward
reduced IGF-I concentrations in the patients with RA (P =
0.08). In the latter study, data from male and female patientsAvailable online http://arthritis-research.com/content/9/4/R73
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with RA were evaluated together, patients had a longer dura-
tion of RA, and they were on stable doses of prednisone and/
or methotrexate – all of which may have confounded the
authors' observations. Other studies have measured GH
secretion after stimulation with GH-releasing hormone [7] or
insulin-induced hypoglycemia [9,17] rather than assessing
spontaneous, diurnal GH secretion (as in this study), render-
ing any comparisons and subsequent conclusions between
the studies difficult. In another study, GH concentrations in
single morning (8 a.m.) samples were elevated approximately
fivefold in RA patients taking glucocorticoids as compared
with values in healthy controls, whereas IGF-I and IGFBP-3
levels were similar in the two groups [18]. Although we are
unaware of reports in which IGF-I and IGFBP responses to
exogenous GH have been compared in patients with RA and
healthy control subjects, the present study and other studies
suggest that RA is associated with GH resistance or
insensitivity.
The effects of RA per se on the HPA axis have been reported
in multiple studies [8,9,32]. To date, there has been no con-
sistent demonstration of altered basal or stimulated cortisol
production in RA patients as compared with healthy individu-
als [32]. However, the presence of 'normal' cortisol levels in
the face of increased secretion of cytokines (IL-6) has been a
consistent finding, leading some to suggest that RA is charac-
terized by a state of 'relative hypocortisolism,' with an inade-
quate anti-inflammatory response to inflammation [32-34]. In
our study, patients with RA exhibited elevated morning ESR,
CRP, and IL-6 concentrations but had no alteration in pulsatile,
nycthemeral, or entropic features of spontaneous cortisol
secretion. Diminished adrenal androgens have been reported
in premenopausal women with RA [35-37]. In these studies,
dehydroepiandrosterone sulfate (DHEAS) and to a lesser
extent DHEA, concentrations in single morning samples were
lower in patients with RA. Additionally, Cutolo and colleagues
[38] reported that morning DHEA levels were inversely related
to the ESR and that the DHEA response to adrenocortico-
tropic hormone (ACTH) stimulation was decreased in premen-
opausal women with RA. To our knowledge, the current study
is the first to report spontaneous, diurnal DHEA secretion in
patients with active RA. Prior findings of diminished DHEAS
levels, coupled with our observation of unaltered circadian
DHEA secretion in patients with RA, might be explained in part
by a decreased conversion of DHEAS to DHEA resulting from
excess proinflammatory cytokines, as has been reported in
synovial fluid from patients with RA [37]. Moreover, our DHEA
findings further suggest that in the setting of heightened
inflammatory and cytokine burden, there is a relative adreno-
cortical androgen insufficiency in patients with RA. In support
of this view, neutralization of IL-6 increases androgen secre-
tion in patients with RA [39].
Glucocorticoids exert negative feedback control on the HPA
axis by suppressing hypothalamic CRH production and ACTH
secretion. The time required to achieve suppression and
recovery is variable and is dependent upon the route, dosage,
duration, and dosing schedule [40]. Due to suppressive
effects of corticosteroid use in patients with RA, we cannot
entirely rule out persistent impairment of HPA activity. Four of
the patients with RA had taken glucocorticoids, with a cumu-
lative exposure in each that was not more than 3 months, and
all patients with RA had been off steroids for at least 3 months
prior to study enrollment. In addition, there were no differences
in early a.m. or peak plasma concentrations of cortisol, ACTH,
or DHEA. Adrenal androgen secretion is more sensitive than
cortisol production to the suppressive effects of glucocorti-
coid therapy [41]. In this study, basal and peak DHEA levels
are unchanged in RA patients as compared with healthy indi-
viduals. Moreover, IL-6 is known to stimulate cortisol and
androgen production in an ACTH-independent fashion
[39,42]. These findings, in concert with the relatively short
duration of past glucocorticoid therapy, suggest that the nor-
mal levels of cortisol in patients with RA in this study are less
likely (but cannot be ruled out entirely) due to an impaired HPA
axis by prior steroid use.
Our patients with RA exhibited reduced LBM, consistent with
findings in other studies [1,19]. The decrease in lean mass
was especially evident in the legs and was accompanied by
diminished serum concentrations of creatinine, an established
index of skeletal muscle mass. Cachexia, characterized by the
loss of body cell mass and function, frequently occurs in
patients with RA. Relative hyposomatotropism, due to reduced
activity of GH/IGF-I axis and the associated negative anabolic
balance resulting from abnormalities in cytokine, cortisol, and
adrenal steroid production and action, have been proposed to
play significant roles in rheumatoid cachexia [4].
Several limitations of this study deserve comment. Because of
strict inclusion and exclusion criteria, the accrual of patients
with RA was below the intended number of subjects planned.
Consequently, we consider any results of interest to be hypo-
thesis-generating, in that they require confirmation in an
independent, larger group of patients. Additionally, the relative
homogeneity of our study population does not allow for extrap-
olation of our findings to postmenopausal women or men.
Finally, quality and quantity of sleep were not measured, and
their possible influences on circadian rhythms of the hormones
measured could not be ascertained.
Conclusion
The current study suggests that active RA in pre- and perimen-
opausal women is characterized by a state of relative GH
insensitivity and diminution in diurnal cortisol and DHEA
secretion, given the chronic inflammatory state of the patients.
Whether these combined somatotropic and adrenocortical
abnormalities in a proinflammatory cytokine milieu exacerbate
the inflammatory process and play a role in the pathogenesis
of rheumatoid cachexia remains to be determined.Arthritis Research & Therapy    Vol 9 No 4    Blackman et al.
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